ARTICLE | Strategy

Arbiter of value

How ICER is becoming the U.S.’s de facto HTA agency

March 23, 2018 9:44 PM UTC

The Institute for Clinical and Economic Review is rapidly becoming the closest thing the U.S. has to an HTA agency.

As an independent, non-governmental body, ICER does not have the authority over reimbursement decisions accorded to European health technology assessment (HTA) agencies. U.S. payers are not required to reimburse drugs ICER determines to be cost-effective. ...